ALGS - Aligos to advance development of oral drug candidate ALG-097558 for COVID-19

Aligos Therapeutics (NASDAQ:ALGS +7.0%) said it had selected oral protease inhibitor ALG-097558 as its drug candidate for the treatment and prevention of COVID-19. The company said its drug ALG-097558 has shown superior potency compared to nirmatrelvir (PF-07321332) against SARS-CoV-2 and multiple resistant variants in all cell-based assays tested to date. The drug demonstrates a 10-fold improvement in cell-based potency against the Omicron variant, when compared to nirmatrelvir, the company said. The drug development is part of the collaboration and license agreement with KU Leuven and its drug discovery unit and investment fund Centre for Drug Design and Discovery (CD3). Aligos expects to file a Phase 1 clinical trial application in 2H 2022.

For further details see:

Aligos to advance development of oral drug candidate ALG-097558 for COVID-19